Cytosorbents Corporation (NASDAQ:CTSO – Free Report) – Research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Cytosorbents in a report released on Thursday, May 14th. HC Wainwright analyst S. Lee now anticipates that the medical research company will post earnings of ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cytosorbents’ Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.03 EPS, FY2028 earnings at $0.06 EPS and FY2029 earnings at $0.08 EPS.
A number of other research firms also recently commented on CTSO. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Thursday, March 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.38.
Cytosorbents Price Performance
NASDAQ:CTSO opened at $0.48 on Tuesday. Cytosorbents has a 52 week low of $0.45 and a 52 week high of $1.39. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 4.70. The company has a market capitalization of $30.08 million, a P/E ratio of -2.52 and a beta of 1.43. The stock’s fifty day moving average is $0.63 and its two-hundred day moving average is $0.67.
Cytosorbents (NASDAQ:CTSO – Get Free Report) last posted its earnings results on Wednesday, May 13th. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Cytosorbents had a negative net margin of 31.85% and a negative return on equity of 235.57%. The business had revenue of $8.86 million during the quarter, compared to analysts’ expectations of $9.40 million.
Institutional Investors Weigh In On Cytosorbents
A number of institutional investors have recently modified their holdings of the company. Avenir Corp grew its stake in shares of Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after buying an additional 147,261 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after buying an additional 79,535 shares in the last quarter. CM Management LLC grew its stake in shares of Cytosorbents by 14.6% in the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock valued at $944,000 after buying an additional 188,372 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Cytosorbents in the third quarter valued at $161,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Cytosorbents in the third quarter valued at $105,000. 32.87% of the stock is owned by institutional investors and hedge funds.
About Cytosorbents
Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.
CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.
Featured Stories
- Five stocks we like better than Cytosorbents
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.
